RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
65 hedge funds and large institutions have $428M invested in RAPT Therapeutics in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 8 closing their positions.
3,128% more call options, than puts
Call options by funds: $7.13M | Put options by funds: $221K
216% more capital invested
Capital invested by funds: $136M → $428M (+$292M)
188% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 8
87.53% more ownership
Funds ownership: 12.82% → 100.35% (+88%)
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
30% more funds holding
Funds holding: 50 → 65 (+15)
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
+$10.2M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$8.05M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$7.6M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$7.04M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
-$15.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$9.24M |
| 3 |
O
OrbiMed
New York
|
-$7.27M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$4.3M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$3.6M |
RAPT Hedge Fund Activity: Q3 2025 in Review
65 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q3 2025, worth a combined $428M — up 216% from $136M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RAPT positions and 8 closed out — a net gain of 15 holders — while 11 added to existing stakes and 19 trimmed.
The largest buyer was Boone Capital Management, opening a new position worth an estimated $10.2M. The largest seller was Column Group, cutting an estimated $15.2M.
- 65 institutional investors held RAPT Therapeutics (RAPT) as of Q3 2025, up from 50 in Q2 2025.
- Funds reported $428M of RAPT Therapeutics stock for Q3 2025, up 216% quarter-over-quarter.
- 23 funds opened new RAPT Therapeutics positions in Q3 2025 and 8 closed out, a net change of +15 holders.
- The largest RAPT Therapeutics buyer in Q3 2025 was Boone Capital Management, an estimated $10.2M added.
- The largest RAPT Therapeutics seller in Q3 2025 was Column Group, an estimated $15.2M sold.
Based on aggregated 13F filings for Q3 2025.